glp-1 obesity drug news october 21 2025 Agonists Market Report 2025-2033, By Product, Molecule, and Geo GLP-1s and Obesity Coverage: Differing
Description
Mkimattila S, Salo M, Hilli J, Pykk S, Yki-Jrvinen H
real-world studies are more reflective of clinical practice but are prone to indication bias and attrition
Who should not take Mounjaro or other GLP-1 medicines
When an individual goes rogue it can be a real safety concern so also understanding why may be necessary, she continued
